The Latest Cardiac and Vascular News
DURHAM, N.C., Aug. 14, 2023 (GLOBE NEWSWIRE) — Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced financial results for the second quarter ended June 30, 2023, and highlighted recent corporate accomplishments. “Humacyte has made significant strides in the […]
DURHAM, N.C., July 26, 2023 (GLOBE NEWSWIRE) — Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced completion of enrollment of its Phase 2/3 vascular trauma trial (V005) that is expected to support a BLA filing for Humacyte’s HAV […]
– Human Acellular Vessel™ (HAV™) granted second RMAT designation by the FDA, for Vascular Trauma – – Completion of enrollment in Phase 3 trial of HAV in Hemodialysis Access in End-Stage Renal Disease Patients – – Conference call and live webcast at 8:00 a.m. ET today – DURHAM, N.C., May […]
HAV granted second RMAT designation by the FDA RMAT will support Humacyte’s lead indication in Vascular Trauma DURHAM, N.C., May 04, 2023 (GLOBE NEWSWIRE) — Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, has been recently granted the U.S. Food […]
— Enrollment Nearing Completion in Human Acellular Vessel™ (HAV™) Phase 2/3 Trial in Vascular Trauma and Phase 3 Trial in Arteriovenous (AV) Access in Hemodialysis Patients — Multiple publications and scientific meeting presentations highlighting clinical and preclinical HAV results – — Conference call and live webcast at 8:00 a.m. ET today […]
– HAVs observed to provide long-term perfusion to patients with critical limb ischemia – 3D Angiograms show mechanical durability of engineered human blood vessels DURHAM, N.C., Jan. 24, 2023 (GLOBE NEWSWIRE) — Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissues and advanced tissue […]
— Progress Continues in Clinical Development of Human Acellular Vessel™ (HAV™) for Vascular Trauma; BLA Filing Anticipated mid 2023 – — Experience with HAV in Ukrainian War Vascular Trauma Mirrors Clinical Experiences in Civilians in the U.S., High Patency and Low Rates of Amputation and Infection Observed – — Pre-Clinical Studies of Small Diameter […]
Six-month primate HAV CABG model demonstrates patency, recellularization and remodeling resembling native blood vessels HAV may address many limitations of current standard of care grafts used in CABG procedure DURHAM, N.C., Nov. 07, 2022 (GLOBE NEWSWIRE) — Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered […]
HAV™ was utilized to treat multiple patients suffering from shrapnel, gunshot wounds, and mine blast injuries DURHAM, N.C., Sept. 23, 2022 (GLOBE NEWSWIRE) — Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissues, complex tissue systems, and organs at commercial scale, today announced the presentation […]
Lt. General Bruce Green, M.D., USAF-ret. Joins Board of Directors Cindy Cao, Ph.D. Appointed as Chief Regulatory Officer DURHAM, N.C., Sept. 20, 2022 (GLOBE NEWSWIRE) — Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissues, today announced the appointments of two distinguished healthcare professionals […]
